The global auto-injectors market is anticipated to grow at a considerable CAGR of 15% during the forecast period (2022-2028). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launches, and product innovation to remain competitive in the marketplace this is anticipated to positively impact significant market growth. For instance,
Browse the full report description of “Global Auto-Injectors Market Size, Share & Trends Analysis Report by Type (Disposable Autoinjectors, and Reusable Autoinjectors), by Application (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, and Others), and by End-User (Home Care Settings, Hospital & Clinics, and Others) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/auto-injectors-market
• In December 2021, Assertio Holdings, Inc., acquired Otrexup single dose once weekly auto-injector from Antares Pharma, Inc.
• In November 2021, Gerresheimer acquired the IP of a new generation cartridge-based auto-injector of Midas Pharma. This new strategic partnership is for the development and marketing of the new generation auto-injector.
• In September 2021, Owen Mumford launched a new Aidaptus auto-injector platform which is single-use auto-injectors. This injector uses stopper sensing technology and it automatically adapts to the individual stopper. It is available in two different spring strengths to accommodate a variety of drug viscosities.
• In October 2019, Becton, Dickinson, and Company launched BD Intevia 1mL two-step disposable auto-injector that combines auto-injector and pre-fillable syringe in one integrated system. It is a disposable autoinjector2-step push-on-skin device it enables the pharmaceutical industry to adopt it for a variety of drugs.
• In October 2019, AstraZeneca has received US Food and Drug Administration (FDA) approval for Fasenra (benralizumab), in a pre-filled, single-use auto-injector. This device is also approved in the European Union (EU) and currently it is an add-on maintenance treatment for severe eosinophilic asthma in the US, EU, Japan, and other countries
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Application
o By End-User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Ypsomed AG, and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Auto-Injectors Market Report by Segment
By Type
By Applications
By End User
Global Auto-Injectors Market Report by Region
North America
• US
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/auto-injectors-market